On April 7, 2021, the FDA granted regular approval to sacituzumab govitecan hziy Trodelvy for patients with unresectable locally advanced or metastatic triple negative breast cancer who have received two or more prior systemic therapies, at least one of them for metastatic disease is stromectol the same as ivermectin